On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results

被引：0
|
作者：
Goulis, Ioannis [1 ]
Karatapanis, Stylianos [2 ]
Akriviadis, Evangelos A. [1 ]
Deutsch, Melanie [3 ]
Dalekos, George N. [4 ,5 ]
Raptopoulou-Gigi, Maria [3 ]
Mimidis, Konstantinos [6 ]
Germanidis, Georgios [7 ]
Triantos, Christos K. [8 ]
Drakoulis, Christos [9 ]
Chounta, Athina [10 ]
Vafiadis, Irene [11 ]
Hatzis, Grigorios [12 ]
Gagalis, Asterios [13 ]
Vlachogiannakos, Jiannis [11 ]
Zintzaras, Elias [14 ,15 ]
Koulouris, Sokratis [16 ]
Bakalos, George [14 ,16 ]
Papatheodoridis, George V. [3 ]
机构：
[1] Hippokrateion Hosp, Dept Internal Med 4, Thessaloniki, Greece
[2] Rhodes Hosp, Dept Internal Med 1, Rhodes, Greece
[3] Hippokrateion Hosp, Dept Internal Med 2, Athens, Greece
[4] Univ Thessaly, Sch Med, Dept Med, Larisa, Greece
[5] Univ Thessaly, Res Lab Internal Med, Larisa, Greece
[6] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Alexandroupolis, Greece
[7] AHEPA Hosp, Dept Gastroenterol, Internal Med Clin 1, Thessaloniki, Greece
[8] Univ Patras, Sch Med, Dept Gastroenterol, Patras, Greece
[9] Nikaia Hosp, Dept Internal Med 2, Athens, Greece
[10] Univ Hosp ATTIKON, Dept Internal Med, Athens, Greece
[11] Laiko Univ, Gen Hosp, Dept Internal Med Propaedeut, Athens, Greece
[12] Laikon Gen Hosp, Physiopathol Dept, Athens, Greece
[13] Papageorgiou Gen Hosp, Dept Gastroenterol, Thessaloniki, Greece
[14] Univ Thessaly, Sch Med, Dept Biomath, Larisa, Greece
[15] Tufts Univ, Sch Med, Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA
[16] Roche Hellas, Med Affairs, Athens, Greece
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1015
引用
收藏
页码：697A / 698A
页数：2
相关论文
共 50 条
  • [21] Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
    Rijckborst, Vincent
    Hansen, Bettina E.
    Ferenci, Peter
    Brunetto, Maurizia R.
    Tabak, Fehmi
    Cakaloglu, Yilmaz
    Lanza, A. Galeota
    Messina, Vincenzo
    Iannacone, Claudio
    Massetto, Benedetta
    Regep, Loredana
    Colombo, Massimo
    Janssen, Harry L. A.
    Lampertico, Pietro
    JOURNAL OF HEPATOLOGY, 2012, 56 (05) : 1006 - 1011
  • [22] EFFECTIVENESS OF PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE AND HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B: FINAL RESULTS 3 YEARS POST-TREATMENT OF THE PROSPECTIVE, GLOBAL, OBSERVATIONAL S-COLLATE STUDY
    Marcellin, P.
    Xie, Q.
    Paik, S. W.
    Flisiak, R.
    Piratvisuth, T.
    Petersen, J.
    Asselah, T.
    Cornberg, M.
    Ouzan, D.
    Foster, G. R.
    Papatheodoridis, G. V.
    Messinger, D.
    Regep, L.
    Bakalos, G.
    Alshuth, U.
    Wedemeyer, H.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S598 - S599
  • [23] ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
    Lau, G. K. K.
    Marcellin, P.
    Brunetto, M.
    Piratvisuth, T.
    Kapprell, H. -P
    Messinger, D.
    Popescu, M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S333 - S333
  • [24] Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
    Piratvisuth, Teerha
    Lau, George
    Chao, You-Chen
    Jin, Rui
    Chutaputti, Anuchit
    Zhang, Q. -B.
    Tanwandee, Tawesak
    Button, Peter
    Popescu, Matei
    HEPATOLOGY INTERNATIONAL, 2008, 2 (01) : 102 - 110
  • [25] Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
    Teerha Piratvisuth
    George Lau
    You-Chen Chao
    Rui Jin
    Anuchit Chutaputti
    Q.-B. Zhang
    Tawesak Tanwandee
    Peter Button
    Matei Popescu
    Hepatology International, 2008, 2 : 102 - 110
  • [26] HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS TREATED WITH PEGINTERFERON ALFA-2A IS ASSOCIATED WITH SUSTAINED RESPONSE UP TO 5 YEARS POST-TREATMENT: PATIENTS WITH CONTINUOUS HBSAG DECLINE STARTING BEFORE WEEK 24 ACHIEVE HIGHEST RATES OF RESPONSE
    Brunetto, Maurizia R.
    Marcellin, Patrick
    Bonino, Ferruccio
    Kapprell, Hans-Peter
    Messinger, Diethelm
    Batrla, Richard
    HEPATOLOGY, 2009, 50 (04) : 519A - 519A
  • [27] Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment
    Jia, Ji-Dong
    Piratvisuth, Teerha
    Lau, George K. K.
    Luo, Kang-Xian
    Jin, Rui
    Lu, Zhi-Meng
    Marcellin, Patrick
    Popescu, Matei
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A88 - A88
  • [28] A FINITE COURSE OF PEGINTERFERON ALFA-2A RESULTS IN INACTIVE CHRONIC HEPATITIS B AND HBSAG CLEARANCE 5 YEARS POST-TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE DISEASE: BASELINE CHARACTERISTICS AND PREDICTIVE FACTORS OF LONG-TERM RESPONSE
    Marcellin, Patrick
    Piratvisuth, Teerha
    Brunetto, Maurizia R.
    Bonino, Ferruccio
    Farci, Patrizia
    Yurdaydin, Cihan
    Gurel, Selim
    Kapprell, Hans-Peter
    Messinger, Diethelm
    Batrla, Richard
    HEPATOLOGY, 2009, 50 (04) : 487A - 487A
  • [29] Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis
    Boglione, Lucio
    Cariti, Giuseppe
    Ghisetti, Valeria
    Burdino, Elisa
    Di Perri, Giovanni
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (06) : 1047 - 1052
  • [30] The cost effectiveness analysis of treatment with peginterferon alfa-2a (40KD) in patients with hbeag-negative chronic hepatitis B
    Kowalik, E.
    Niewada, M.
    Jakubczyk, M.
    Horban, A.
    Berak, H.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2006, 9 (06) : A300 - A300
12345